Peptide Comparison
TabimorelinvsCJC-1295 with DAC
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
At a Glance
Quick
comparison
Dose Range
Tabimorelin
100–500 mg
CJC-1295 with DAC
1000–2000 mcg
Frequency
Tabimorelin
Once daily
CJC-1295 with DAC
Twice weekly
Administration
Tabimorelin
Oral (capsule or solution)
CJC-1295 with DAC
Subcutaneous injection
Cycle Length
Tabimorelin
4-6 weeks
CJC-1295 with DAC
8-12 weeks
Onset Speed
Tabimorelin
Moderate (1-2 weeks)
CJC-1295 with DAC
Moderate (1-2 weeks)
Evidence Level
Tabimorelin
Moderate human trials (Phase 1-2)
CJC-1295 with DAC
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Growth Hormone Stimulation
Convenience & Compliance
Selectivity & Safety Profile
GH Elevation
Convenience
Recovery Support
Technical Data
Compound
specifications
Tabimorelin
Molecular Formula
C32H40N4O3
Molecular Weight
528.7 g/mol
Half-Life
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Bioavailability
Orally active with dose-dependent bioavailability (increases at higher doses)
CAS Number
193079-69-5
CJC-1295 with DAC
Molecular Formula
C165H269N47O46
Molecular Weight
3647.28 g/mol
Half-Life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Protocols
Dosing
tiers
Tabimorelin
CJC-1295 with DAC
Applications
Best
suited for
Tabimorelin
+Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation
+Orally active—no injections required, making it convenient for daily use
+Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses
+Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides
+Well-tolerated in short-term human studies with generally mild adverse effects
CJC-1295 with DAC
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Safety Profile
Side
effects
Tabimorelin
Common
- Headache
- Nausea
- Appetite stimulation
- Dizziness
- Dry mouth
Serious
- Drug-drug interactions via CYP3A4 inhibition
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
Research Status
Safety
& evidence
Tabimorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Contraindications
- xActive or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
- xConcurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
- xUntreated thyroid dysfunction
- xUncontrolled diabetes
CJC-1295 with DAC
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- xActive cancer or history of malignancy
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xDiabetic retinopathy
- xUncontrolled diabetes
Decision Guide
Which is
right for you?
Choose Tabimorelin if...
- Stimulating growth hormone production in healthy individuals
- Exploring GH secretagogue mechanisms in research settings
- Patients preferring oral administration over injections
Choose CJC-1295 with DAC if...
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity